Correlation Between GeneReach Biotechnology and Advanced Lithium

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both GeneReach Biotechnology and Advanced Lithium at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining GeneReach Biotechnology and Advanced Lithium into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between GeneReach Biotechnology and Advanced Lithium Electrochemistry, you can compare the effects of market volatilities on GeneReach Biotechnology and Advanced Lithium and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in GeneReach Biotechnology with a short position of Advanced Lithium. Check out your portfolio center. Please also check ongoing floating volatility patterns of GeneReach Biotechnology and Advanced Lithium.

Diversification Opportunities for GeneReach Biotechnology and Advanced Lithium

-0.43
  Correlation Coefficient

Very good diversification

The 3 months correlation between GeneReach and Advanced is -0.43. Overlapping area represents the amount of risk that can be diversified away by holding GeneReach Biotechnology and Advanced Lithium Electrochemis in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Advanced Lithium Ele and GeneReach Biotechnology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on GeneReach Biotechnology are associated (or correlated) with Advanced Lithium. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Advanced Lithium Ele has no effect on the direction of GeneReach Biotechnology i.e., GeneReach Biotechnology and Advanced Lithium go up and down completely randomly.

Pair Corralation between GeneReach Biotechnology and Advanced Lithium

Assuming the 90 days trading horizon GeneReach Biotechnology is expected to generate 167.24 times less return on investment than Advanced Lithium. But when comparing it to its historical volatility, GeneReach Biotechnology is 5.38 times less risky than Advanced Lithium. It trades about 0.0 of its potential returns per unit of risk. Advanced Lithium Electrochemistry is currently generating about 0.14 of returns per unit of risk over similar time horizon. If you would invest  3,750  in Advanced Lithium Electrochemistry on September 1, 2024 and sell it today you would earn a total of  550.00  from holding Advanced Lithium Electrochemistry or generate 14.67% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

GeneReach Biotechnology  vs.  Advanced Lithium Electrochemis

 Performance 
       Timeline  
GeneReach Biotechnology 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days GeneReach Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in December 2024. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.
Advanced Lithium Ele 

Risk-Adjusted Performance

7 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Advanced Lithium Electrochemistry are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, Advanced Lithium showed solid returns over the last few months and may actually be approaching a breakup point.

GeneReach Biotechnology and Advanced Lithium Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with GeneReach Biotechnology and Advanced Lithium

The main advantage of trading using opposite GeneReach Biotechnology and Advanced Lithium positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if GeneReach Biotechnology position performs unexpectedly, Advanced Lithium can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Advanced Lithium will offset losses from the drop in Advanced Lithium's long position.
The idea behind GeneReach Biotechnology and Advanced Lithium Electrochemistry pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.

Other Complementary Tools

Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Transaction History
View history of all your transactions and understand their impact on performance
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance